Brief: Sellas Life Sciences Receives Fast Track Designation From FDA
30/10/2023 13:06
Oct 30 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES RECEIVES FAST TRACK DESIGNATION FROM
FDA
FOR SLS009 FOR TREATMENT OF RELAPSED/REFRACTORY PERIPHERAL
T-CELL LYMPHOMAS
* SELLAS LIFE SCIENCES GROUP INC - ACTIVELY PURSUING
POTENTIAL
BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR SLS009 FOR
TREATMENT OF R/R PTCL
Source text for Eikon: ID:nGNX2rXJYP
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses